Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 in cognitive impairment associated with Huntington's disease
ISRCTN17896603Phase 2Completed
- Sponsor
- Sage Therapeutics
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing SAGE-718 with Placebo (2 arms). Primary endpoint: Change from baseline to day 84 in cognitive function assessed using the Symbol Digit Modalities Test. Started Nov 2021; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on ISRCTN17896603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17896603.